Ansbert Gadicke, M.D.

Dr. Ansbert Gadicke is Managing Partner of MPM BioImpact. Ansbert founded MPM in 1992 as a biotech venture capital firm and subsequently expanded the firm across private and public biotechnology investing. He has been a lead investor and board member in companies that have helped improve lives around the world, including BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), TriNetX, Pharmasset (acquired by Gilead Sciences), Cullinan Therapeutics (NASDAQ: CGEM), ElevateBio, Orna & ReNAgade Therapeutics (acquired by Eli Lilly) and K2 Therapeutics.

Among these investments, Pharmasset developed Sovaldi, a breakthrough curative treatment for hepatitis C and one of the most successful product launches in pharmaceutical industry history, which has helped cure more than six million people worldwide. Prior to founding MPM, Ansbert was a consultant at The Boston Consulting Group.

Ansbert is a recipient of the 2017 Global Oncology Visionary Award and is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, he studied HPV16 and HPV18 in Prof. Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). He has published research in leading scientific journals including Nature and Cell.